Novartis to spin off its Sandoz generics and biosimilars unit
By Plan continues Big Pharma move away from generics and consumer healthcare to focus on patented drugs
Hit enter after type your search item
Plan continues Big Pharma move away from generics and consumer healthcare to focus on patented drugs